Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer

被引：29

作者：

Nowsheen S. ^{[1
]}

Viscuse P.V. ^{[2
]}

O’Sullivan C.C. ^{[3
]}

Sandhu N.P. ^{[4
]}

Haddad T.C. ^{[3
]}

Blaes A. ^{[5
]}

Klemp J. ^{[6
]}

Nhola L. ^{[7
]}

Herrmann J. ^{[8
]}

Ruddy K.J. ^{[3
]}

机构：

[1] Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic School of Medicine and the Mayo Clinic Medical Scientist Training Program, Rochester, MN

[2] Department of Medicine, Mayo Clinic, Rochester, MN

[3] Division of Medical Oncology, Mayo Clinic, 200 First St. SW, Rochester, 55905, MN

[4] Division of General Internal Medicine, Mayo Clinic, Rochester, MN

[5] Department of Medicine, University of Minnesota, Rochester, MN

[6] Division of Clinical Oncology, University of Kansas Medical Center, Wichita, KS

[7] Division of Cardiology Research, Mayo Clinic, Rochester, MN

[8] Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN

来源：

Current Breast Cancer Reports | 2017年 / 9卷 / 3期

基金：

美国国家卫生研究院;

关键词：

Breast cancer; Cardio-oncology; Cardiomyopathy; Cardiotoxicity; HER2; Trastuzumab;

D O I：

10.1007/s12609-017-0249-4

中图分类号：

学科分类号：

摘要：

Purpose of Review: Treatment with trastuzumab is a cornerstone of human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer treatment, but carries an unfortunate risk of toxicity to the cardiovascular system. Here, we review recent findings on trastuzumab-associated cardiotoxicity, focusing on its incidence, diagnosis, and treatment. Recent Findings: Screening with multigated acquisition scan (MUGA) or echocardiogram (ECHO) is recommended to assess cardiac function prior to and during trastuzumab therapy. Because trastuzumab-induced cardiotoxicity is typically reversible, cessation of trastuzumab and/or administration of first-line heart failure agents effectively restores cardiac function in most cases. Severe trastuzumab-induced cardiotoxicity is rare enough that the risk-benefit ratio still weighs in favor of its use in the vast majority of patients with HER2+ breast cancer. Summary: An improved understanding of the pathophysiology underlying trastuzumab-induced cardiotoxicity and the identification of patients at highest risk will allow us to continue to safely administer trastuzumab in patients with breast cancer. © 2017, Springer Science+Business Media, LLC.

引用

页码：173 / 182

页数：9

共 91 条

[1]

Cancer treatment & survivorship facts & figures, (2017)

[2]

Smith L.A., Cornelius V.R., Plummer C.J., Levitt G., Verrill M., Canney P., Et al., Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials, BMC Cancer, 10, (2010)

[3]

Darby S.C., Ewertz M., McGale P., Bennet A.M., Blom-Goldman U., Bronnum D., Et al., Risk of ischemic heart disease in women after radiotherapy for breast cancer, N Engl J Med, 368, 11, pp. 987-998, (2013)

[4]

American Cancer Society, (2017)

[5]

Krause D.S., Van Etten R.A., Tyrosine kinases as targets for cancer therapy, N Engl J Med, 353, 2, pp. 172-187, (2005)

[6]

Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., Et al., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J Clin Oncol, 20, 3, pp. 719-726, (2002)

[7]

Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 11, pp. 783-792, (2001)

[8]

Baselga J., Carbonell X., Castaneda-Soto N.-J., Clemens M., Green M., Harvey V., Et al., Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule, J Clin Oncol, 23, 10, pp. 2162-2171, (2005)

[9]

Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., Et al., Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer administered as first-line treatment: the M77001 study group, J Clin Oncol, 23, 19, pp. 4265-4274, (2005)

[10]

Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Et al., Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer, N Engl J Med, 353, 16, pp. 1659-1672, (2005)

← 1 2 3 4 5 6 7 8 9 10 →